Float Short %

2.98

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

0.54

EPS Last/This Y

0.19

EPS This/Next Y

0.6

Price

3.31

Target Price

20.5

Analyst Recom

Performance Q

-3.22

Relative Volume

0.71

Beta

1.63

Ticker: LTRN

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-03-03	LTRN	3.71	0.03	0.07	596
2025-03-04	LTRN	3.88	0.03	0.07	596
2025-03-05	LTRN	3.84	0.03	0.00	607
2025-03-06	LTRN	3.76	0.03	0.00	607
2025-03-07	LTRN	3.72	0.03	0.00	598
2025-03-10	LTRN	3.45	0.03	0.00	600
2025-03-11	LTRN	3.57	0.03	0.00	600
2025-03-12	LTRN	3.84	0.03	0.00	600
2025-03-13	LTRN	3.62	0.03	0.00	600
2025-03-14	LTRN	3.66	0.02	0.00	657
2025-03-17	LTRN	3.93	0.02	0.00	657
2025-03-18	LTRN	3.85	0.02	999.99	658
2025-03-19	LTRN	3.75	0.02	0.00	657
2025-03-20	LTRN	3.65	0.02	0.00	657
2025-03-21	LTRN	3.71	0.02	0.00	657
2025-03-24	LTRN	3.99	0.03	2.73	541
2025-03-25	LTRN	3.85	0.08	0.00	582
2025-03-26	LTRN	3.65	0.08	0.00	580
2025-03-27	LTRN	3.74	0.08	0.00	580
2025-03-28	LTRN	3.5	0.08	0.00	580
2025-03-31	LTRN	3.54	0.08	0.00	580
2025-04-01	LTRN	3.32	0.08	0.00	580
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-03-03	LTRN	3.71	-34.2	-	-1.93
2025-03-04	LTRN	3.80	-34.2	-	-1.93
2025-03-05	LTRN	3.89	-34.2	-	-1.93
2025-03-06	LTRN	3.99	-34.2	-	-1.93
2025-03-07	LTRN	3.61	-34.2	-	-1.93
2025-03-10	LTRN	3.62	-34.2	-	-1.93
2025-03-11	LTRN	3.52	-34.2	-	-1.93
2025-03-12	LTRN	3.74	-34.2	-	-1.93
2025-03-13	LTRN	3.74	-34.2	-	-1.93
2025-03-14	LTRN	3.80	-34.2	-	-1.93
2025-03-17	LTRN	3.93	-34.2	-	-1.93
2025-03-18	LTRN	3.75	-34.2	-	-1.93
2025-03-19	LTRN	3.75	-34.2	-	-1.93
2025-03-20	LTRN	3.72	-34.2	-	-1.93
2025-03-21	LTRN	3.72	-34.2	-	-1.93
2025-03-24	LTRN	3.90	-34.2	-	-1.93
2025-03-25	LTRN	3.85	-34.2	-	-1.93
2025-03-26	LTRN	3.65	-34.2	-	-1.93
2025-03-27	LTRN	3.68	-34.2	-	-1.93
2025-03-28	LTRN	3.55	-34.2	-	-1.93
2025-03-31	LTRN	3.54	-	-	-1.74
2025-04-01	LTRN	3.31	-	-	-1.74
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-03-03	LTRN	0.00	-3.21	2.77
2025-03-04	LTRN	0.00	-3.21	2.77
2025-03-05	LTRN	0.00	-3.21	2.77
2025-03-06	LTRN	0.00	-3.21	2.77
2025-03-07	LTRN	0.00	-3.21	2.77
2025-03-10	LTRN	0.00	-3.21	2.77
2025-03-11	LTRN	0.00	-3.21	2.77
2025-03-12	LTRN	0.00	-3.21	2.89
2025-03-13	LTRN	0.00	-3.21	2.89
2025-03-14	LTRN	0.00	-3.21	2.89
2025-03-17	LTRN	0.00	-3.21	2.89
2025-03-18	LTRN	0.00	-3.21	2.89
2025-03-19	LTRN	0.00	-3.21	2.89
2025-03-20	LTRN	0.00	-3.21	2.89
2025-03-21	LTRN	0.00	-3.21	2.89
2025-03-24	LTRN	0.00	-3.21	2.89
2025-03-25	LTRN	0.00	-3.21	2.89
2025-03-26	LTRN	0.00	-3.21	2.98
2025-03-27	LTRN	0.00	-3.21	2.98
2025-03-28	LTRN	0.00	-3.21	2.98
2025-03-31	LTRN	0.00	-3.21	2.98
2025-04-01	LTRN	0.00	-3.21	2.98
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.54

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-3.21

Beta

1.63

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

86.7

Max Drawdown 5-Year %

Target Price

20.5

P/E

Forward P/E

PEG

P/S

P/B

1.68

P/Free Cash Flow

EPS

-1.93

Average EPS Est. Cur. Y

-1.74

EPS Next Y. (Est.)

-1.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.71

Return on Equity vs Sector %

-117.9

Return on Equity vs Industry %

-104.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Lantern Pharma Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 21

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

stock quote shares LTRN – Lantern Pharma Inc Stock Price stock today

news today LTRN – Lantern Pharma Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch LTRN – Lantern Pharma Inc yahoo finance google finance

stock history LTRN – Lantern Pharma Inc invest stock market

stock prices LTRN premarket after hours

ticker LTRN fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: LTRN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y